Bayers, Split

Bayer's Split Verdict: Two Brokers, One Rating, and a Margin Test That Outlasts the Headlines

Published on 11/20/2026 at 16:11 | Editorial boerse-global.de
Jefferies and Berenberg both rate Bayer a hold, yet their targets differ by EUR 13.50, leaving the pharma margin as the decisive test.
Bayers, Split, Verdict, Two, Brokers, One, Rating, Test, That, Outlasts Illustration mit AI erstellt.

Bayer shares slipped 2.3% on Thursday as the broader German equity market softened, but the more telling signal for investors came from the research desks. Both Jefferies and Berenberg are telling clients to hold the stock — yet their price targets now sit EUR 13.50 apart, a gap that says far more about the debate inside Bayer than the shared rating does.

Jefferies, fresh from its London pharma conference, kept its target at EUR 48.50 on Thursday. A day earlier, Berenberg's Sebastian Bray had lifted his from EUR 53.50 to EUR 62.00, according to dpa-AFX, pointing to the possibility of a Monsanto IPO before the end of the decade and the prospect that proceeds could be channelled into pharmaceutical development. Measured from Thursday's close, one target implies upside and the other downside. A "hold" label, in other words, tells you almost nothing about what operating performance actually justifies the price.

The Number Both Camps Are Watching

What separates the two views is not the growth story but the margin behind it. Jefferies reported clearer signs of expansion in Bayer's pharma business after its conference, yet stopped short of upgrading the stock. That is not a contradiction: a brighter read on growth is not proof of higher profitability. The question for shareholders is whether to act on those signals now or wait for them to show up in the reported figures.

Bayer itself has set the bar. With its third-quarter 2026 numbers, the company raised its full-year outlook for the pharma margin, and lifted expectations for group EBITDA before special items and for free cash flow at the same time. That matters because the benchmark now comes from the company's own guidance rather than from any single analyst's model.

For the third quarter of 2026, Bayer reported group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Both figures describe the group as a whole, which makes them a starting point rather than an answer. Higher group revenue alone would not demonstrate that Bayer is earning more per euro of pharma sales.

Should investors sell immediately? Or is it worth buying Bayer?

A Regulatory Win, Without the Arithmetic

The product side of the bull case got a boost last week when the US Food and Drug Administration approved Asundexian, branded Sunharbo, in combination with an antiplatelet agent to reduce the risk of a further stroke in certain adults. The regulatory decision is now in hand.

What the drug can add to operating profit cannot be derived from the approval alone. Until Bayer discloses uptake and contribution, the yardstick remains the trajectory of the pharma business in aggregate.

Two Ways the Story Could Break

The optimistic path requires two things to arrive together: the growth signals Jefferies flagged must be confirmed in the actual business performance, and the margin must meet the raised guidance. Should both land, the growth case would no longer rest on impressions from a conference — Bayer would have supplied a hard data point on profitability as well.

The pessimistic path does not assume the growth signals are wrong. Pharma revenue could climb while the margin still falls short of the upgraded target. That combination would be the one that matters: it would not refute revenue optimism, but it would undercut the case for proportionally stronger earnings power. Berenberg's higher target, tied as it is to a potential Monsanto listing and future pharma funding, is a different kind of catalyst from a margin already being earned in the current business — which limits how much it helps in judging the margin question.

February 24 Is the Reckoning

As long as Bayer delivers on its raised pharma margin guidance while the growth signals hold, the more constructive case gains weight. If the margin lags instead, a revenue beat would be no substitute, and the focus would shift to whether management can explain why growth is not reaching operating profit as expected.

The next checkpoint is expected on 24 February 2027, when fourth-quarter 2026 results are due. On that print, the decisive item is whether reported pharma profitability clears the higher bar Bayer set for itself.

Ad

Bayer Stock: New Analysis - 20 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70540349 |